<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85369">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01993849</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00028506</org_study_id>
    <nct_id>NCT01993849</nct_id>
  </id_info>
  <brief_title>Use of NAC in Fingernail Biting</brief_title>
  <official_title>A Randomized Placebo-controlled Trial of N-Acetylcysteine in Onychophagia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kevin Gray</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <brief_summary>
    <textblock>
      To conduct a pilot randomized placebo-controlled feasibility trial of N-acetylcysteine (NAC)
      in onychophagia, preliminarily assessing the tolerability and effects of this
      pharmacotherapy on young adults who bite their fingernails. It is proposed that NAC will
      help decrease fingernail biting.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of conducting a trial of NAC in fingernail biters.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in rate of fingernail biting</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Craving for nail biting</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Measurement of nail length</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Onychophagia</condition>
  <arm_group>
    <arm_group_label>NAC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Twice daily dosing for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Twice daily dosing for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-Acetylcysteine (NAC)</intervention_name>
    <arm_group_label>NAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Age 18-30 2. Fingernail biter for â‰¥5 years

        Exclusion Criteria:

          -  1. Any unstable major DSM-IV Axis I psychiatric disorder in the past month (e.g.,
             psychotic disorders, bipolar disorder, major depressive disorder) 2. Current
             substance dependence in the past month 3. Current unstable major medical disorder or
             medical condition in the past 6 months (e.g., renal impairment) 4. Current pregnancy
             or breastfeeding 5. Current seizure disorder or asthma, due to possible elevated risk
             for adverse effects with NAC in individuals with these conditions 6. Known
             hypersensitivity to NAC 7. Use of carbamazepine or nitroglycerin (or any other
             medication deemed to be hazardous if taken with NAC) within 14 days of study
             participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 7, 2016</lastchanged_date>
  <firstreceived_date>September 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Kevin Gray</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Anxiety</keyword>
  <keyword>Impulse control</keyword>
  <keyword>Depression</keyword>
  <keyword>ADHD</keyword>
  <keyword>Fingernail Biting</keyword>
  <keyword>N-Acetylcysteine</keyword>
  <keyword>NAC</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
